Mesoblast (MESO) Stock Price
Mesoblast Price
Revenue has compounded at 25.2% per year over the past 19 years to 120.25 M USD. Mesoblast's net margin stands at -47.8%, up from -894.6% several years earlier. Analysts set a median price target of 11.50 USD, implying 19.1% below the current price. Of 10 analysts, 9 rate the stock a buy — an overall Buy consensus.
Mesoblast stock price
Mesoblast business model & stock analysis
Frequently asked questions about Mesoblast
Analysts currently set an average price target of 11.50 USD for the Mesoblast stock (median: 11.50 USD), implying -19.1 % versus the latest price. The consensus is based on 10 analyst ratings.
10 analysts currently rate the Mesoblast stock: 9 recommend buying, 1 holding and 0 selling.
Converted at the current exchange rate, the Mesoblast share trades at 12.68 EUR (14.21 USD).
The revenue of Mesoblast is 120.25 M USD. This figure is based on current financial data and reflects the company's business performance.
The profit of Mesoblast is -57.50 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Mesoblast is currently -320.05. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Mesoblast stock.
The price-to-sales ratio (P/S) of Mesoblast is currently 153.04. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Mesoblast stock.
The Eulerpool Quality Score for Mesoblast is 4/10.
The ISIN of Mesoblast is US5907171046. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Mesoblast is A2AA6U. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Mesoblast is MESO. The ticker symbol is used to trade Mesoblast shares on the stock exchange.
Mesoblast stock
Mesoblast Peer Group
All fundamentals and in-depth analysis of Mesoblast
Our stock analysis for Mesoblast stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Mesoblast. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.